Filing Flows › Comparisons › ENSC vs NRXP
Ensysce Biosciences vs NRX Pharmaceuticals: ENSC and NRXP compared
Ensysce Biosciences is the larger company: $1.2M of revenue in its latest quarter (Q2 2026) against $1.1M for NRX Pharmaceuticals (Q2 2026). Ensysce Biosciences is more profitable, with an operating margin of -221.3% against -590.8%.
Where the money goes: ENSC and NRXP
Ensysce Biosciences (ENSC) · Q2 2026
Ensysce Biosciences, Q2 2026: revenue $1.2M (-15% year over year), operating margin -221.3%, net loss $2.6M, operating cash flow −$2.0M. The chart follows the revenue to costs, profit and cash.
NRX Pharmaceuticals (NRXP) · Q2 2026
NRX Pharmaceuticals, Q2 2026: revenue $1.1M, operating margin -590.8%, net loss $16.5M, operating cash flow −$8.9M. The chart follows the revenue to costs, profit and cash.
| Ensysce Biosciences (ENSC) | NRX Pharmaceuticals (NRXP) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q2 2026 |
| Revenue | $1.2M | $1.1M |
| Revenue growth, Y/Y | -15% | — |
| Operating margin | -221.3% | -590.8% |
| Net earnings | −$2.6M | −$16.5M |
| Net margin | -220.8% | — |
| Operating cash flow | −$2.0M | −$8.9M |
Where the revenue comes from
NRX Pharmaceuticals
- Therapy: $871K (79%)
- Procedures: $230K (21%)
Questions
Which is bigger, Ensysce Biosciences or NRX Pharmaceuticals?
Ensysce Biosciences is the larger company: $1.2M of revenue in its latest quarter (Q2 2026) against $1.1M for NRX Pharmaceuticals (Q2 2026).
Is Ensysce Biosciences or NRX Pharmaceuticals growing faster?
Ensysce Biosciences is more profitable, with an operating margin of -221.3% against -590.8%.
More: Ensysce Biosciences earnings · how Ensysce Biosciences makes money · NRX Pharmaceuticals earnings · how NRX Pharmaceuticals makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 13, 2026; 10-Q filed Aug 14, 2026). Fiscal quarters can end on different dates. Not investment advice.